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PRM28  
PREVALENCE OF THYROID DISORDERS AND NEED FOR UNIVERSAL SCREENING 
OF THYROID DYSFUNCTION IN PREGNANT WOMEN: A META-ANALYSIS  
Bansal D, Kandikatla L, Krishna PSR, Gudala K 
National Institute of Pharmaceutical Education and Research, Mohali, India  
OBJECTIVES: Thyroid dysfunction is the second most common endocrinopathy 
affecting women of childbearing age. Many studies have recommended that 
thyroid function screening should be routinely performed in all pregnant 
women. The aim of the present study was to determine the prevalence of thyroid 
disorders during pregnancy and to evaluate efficiency of the universal screening 
strategy versus case-finding strategy for diagnosing thyroid dysfunctions. 
METHODS: Comprehensive literature search was done in PubMed and EMBASE 
databases till July 2012 for studies related to prevalence and screening of thyroid 
dysfunction. For prevalence, the primary estimate was weighed mean pooled 
prevalence (%) with 95% CI. For screening, the primary estimate was pooled odds 
ratio (OR) with 95% CI. Heterogeneity was assessed by I2 statistics. Publication 
bias was assessed using Begg and Egger test. Sensitivity analysis was also 
performed. RESULTS: A total of 33 studies (1988- 2012) for prevalence and 5 
(2007- 2011) for screening were found to be pertinent. Because of significant 
heterogeneity, a random effects model was chosen. Combined analysis of 
weighed pooled prevalence of 19 studies of Thyroid Auto Immunity found 9.7% 
(9.5-10), 21 studies of hypothyroidism found 3.7% (2.2-6.1) and 10 studies of 
hyperthyroidism found 2.2% (1.0-4.5), 7 studies of overt/ clinical hypothyroidism 
found 2% (0.8-5.1), 13 studies of subclinical hypothyroidism found 3.7% (3-4.7), 6 
studies of hypothyroxinemia found 3.4% (1.2-9.8), 4 studies of overt/ clinical 
hyperthyroidism found 0.6% (0.3-1.4) and 5 studies of subclinical 
hyperthyroidism found 0.022 (1.6-2.9). For the effectiveness of universal 
screening pooled OR was found to be 2.87 (1.60-4.94, P-<0.001). CONCLUSIONS: 
Our analysis supports the hypothesis of higher prevalence of thyroid dysfunction 
in pregnancy especially, hypothyroidism. The universal screening strategy is 
found to be more effective as the case-finding strategy fails to detect the 
majority of pregnant women with thyroid dysfunction.  
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CHALLENGES IN ASSESSING THE IMPACT OF HYPONATREMIA MANAGEMENT 
ON LENGTH OF STAY: INTERIM RESULTS FROM A GLOBAL, MULTI-CENTER, 
PROSPECTIVE, OBSERVATIONAL REGISTRY OF HOSPITALIZED HYPERVOLEMIC 
AND EUVOLEMIC HYPONATREMIC PATIENTS  
Dasta JF1, Amin A2, Chiong JR3, Greenberg A4, Verbalis JG5, Chiodo J6 
1Ohio State University, Columbus, OH, USA, 2University of California-Irvine, Orange, CA, USA, 
3Loma Linda University, Loma Linda, CA, USA, 4Duke University, Durham, NC, USA, 
5Georgetown University, Washington, DC, USA, 6Otsuka America Pharmaceutical, Inc., Princeton, 
NJ, USA  
OBJECTIVES: Hyponatremia (HN) is the most common electrolyte abnormality in 
hospitalized patients. Because of the methodological difficulties, little is known 
regarding the impact and management of HN on patient outcomes and health 
care resource usage. The HN Registry is a novel prospective effort to document 
the clinical management and health care outcomes of HN. METHODS: After 
informed consent or waiver, data were extracted from medical charts of patients 
enrolled in the HN registry. HN was defined as a serum sodium ≤ 130 mmol/L. 
Data from these eligible patients are summarized by sample size (n) and 
percentage (%) for categorical data, and mean and standard deviation for 
continuous data. Since there is no universal definition, length of stay (LOS) was 
calculated in several ways including LOS from date of HN identification (LOS 1), 
LOS from date of HN treatment initiation (LOS 2), and LOS limited to cases where 
treatment started within 2 days of HN identification (LOS 3). RESULTS: A total of 
3795 of the 4909 patients enrolled at 253 (US=160, EU=93) sites between Sept 2010 
and January 2013 had sufficient data for analysis. For fluid restriction, LOS 
1=8.1±8.4, LOS 2=7.4±8.9, LOS 3=7.4±9.0. For pharmacological therapy, LOS 
1=8.7±8.9, LOS 2=7.1±8.2, LOS 7.4±6.9. For hypertonic saline, LOS 1=7.0±7.3, LOS 
2=6.1±6.0, LOS 3=3.7±2.2, LOS 4=6.3±6.3. CONCLUSIONS: Our analysis shows a 
considerable of LOS variability by HN management and LOS definition. By 
correcting the analysis for baseline factors and outliers, the effect of HN 
management on LOS may become clearer.  
 
PRM30  
OPTIMIZING REAL WORLD DATA COLLECTION FOR COMPARATIVE 
EFFECTIVENESS AND MARKET ACCESS  
Wasserman M, Whitcher C 
Double Helix Consulting, London, UK  
OBJECTIVES: Real world data studies provide a level of granularity that may be 
not be available in randomized clinical trials (RCTs) that have strict inclusive 
exclusion criteria and may lead to weak external validity. Furthermore, RCTs 
generally do not capture important information on adherence, costs and rare 
side effects. The purpose of this study is to understand how to design patient 
registries and other observational studies to optimize their use to support 
market access decisions. METHODS: First, secondary research was conducted by 
analysing existing registries in a given therapeutic area in European markets 
including Belgium, Denmark, France, Germany, Italy, Poland, Spain, Sweden and 
the UK. Data points from existing registries were charted from ‘most’ to ‘least 
prevalent’. Missing attributes that were perceived as essential based on expert 
opinion were also collected, identifying gaps in available data. Second, an 
international payer panel completed a quantitative survey and completed 
primary in depth interviews to understand the relative impact of all the registry 
attributes, including those that were perceived as gaps. This included impact on 
price, reimbursement status and formulary listing. Transferability of data was 
also tested to identify whether payers would accept data from other markets and 
determine what should be collected to maximise market access. RESULTS: Data 
gaps were cross referenced with the payer needs to understand which endpoints 
are not currently being addressed. This allowed an accurate map of critical 
endpoints needed to have the greatest impact on market access. CONCLUSIONS: 
In an era of evidence based medicine and constrained budgets, drug 
manufacturers need to identify how to best utilise real world data and patient 
registries. Using this methodology, it is possible to identify what data to collect 
and where it should be collected in order to maximise the market access 
opportunity and pricing potential.  
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COMPARISON OF INFORMAL CARE TIME AND COSTS IN DIFFERENT  
AGE-RELATED DEMENTIAS: A REVIEW  
Costa N1, Ferlicoq L2, Derumeaux-Burel H2, Rapp T3, Garnault V2, Gillette S2, Andrieu S1, 
Vellas B4, Lamure M5, Grand A2, Molinier L6 
1INSERM, Toulouse, France, 2University hospital of Toulouse, Toulouse, France, 3University of 
Paris Descartes, Paris, France, 4University of Toulouse III, Toulouse, France, 5University of Lyon, 
Bron, France, 6University Hospital of Toulouse, Toulouse, France  
OBJECTIVES: Age-related dementia is a progressive degenerative brain syndrome 
whose prevalence increases with age. Alzheimer disease (AD), Parkinson disease 
(PD), Vascular Dementia (VD) are the most common age-related dementias. 
Dementias cause a substantial burden on society and on families who provide 
informal care. This study aims to review the relevant papers to compare 
informal care time and costs in different age-related dementias. METHODS: A 
systematic bibliographic search was performed on an international medical 
literature database (MEDLINE). All studies which assessed the social economic 
burden of different dementias were selected. Informal care time and costs were 
analyzed by disease stages and in three care settings, at home, in institution and 
without care setting distinction. RESULTS: 21 studies met our criteria. Depending 
on studies, informal costs vary from $1,364 to $44,736 in AD patients at home 
and from $1,563 to $5,386 in PD patients at home. Informal care time vary from 
11,59h to 139,30h per week for AD patient at home and from 10,00h to 22,00h per 
week for PD patients at home. For informal care time and costs in institution 
only papers on AD were available. The annual informal costs vary from $416 to 
$5,542 and informal care time varies from 3.02h to 17.25h per week. For patients 
without distinction of care setting, annual informal costs varies from $1,831to 
$11,251 for AD and informal care time from 12,29h to 66,55h per week. Mean 
informal care time per week for patient at home was 55.73 h in AD and 15.8 h in 
PD (p=0.0076) and the associated mean annual informal costs were $17,492 
versus $3,284, respectively (p=0.0393). CONCLUSIONS: There is a lack of data 
about informal care time and costs among other dementias than AD or PD. 
Globally, AD is most costly in terms of informal care costs than PD.  
 
PRM32  
TRENDS IN THE COST AND CHARGES FOR A HOSPITAL ADMISSION FOR ACUTE 
ISCHEMIC STROKE (AIS) IN THE UNITED STATES: DO THE TRENDS TRACK 
WITH THE CONSUMER PRICE INDEX (CPI) FOR MEDICAL CARE SERVICES?  
Simpson AN, Simpson KN 
Medical University of South Carolina, Charleston, SC, USA  
OBJECTIVES: The use of effective but high cost interventions and improved 
survival may affect the cost of a hospital admission. Thus, hospital costs for AIS 
may be expected to increase more than the average cost of medical care, as 
measured by the CPI, as the mix of cases change. The purpose of the study was 
to compare the actual trends in costs and charges for hospital admissions for AIS 
with the CPI, both overall and by use of tPA and mechanical thrombectomy (MT). 
METHODS: A total of 499,661 hospital admissions for AIS were extracted from 
the Nationwide Inpatient Sample (NIS), Healthcare Cost and Utilization Project 
(HCUP) data for 2005-2010. Cost per admission was estimated from total charges 
using each hospital’s cost-to-charge ratio and were compared with CPI trends in 
changes in health care costs provided by the US Bureau of Labor and Statistics. 
Use of tPA and/or MT was examined using multiple regression analyses. 
RESULTS: Cost of an acute care admission for AIS increased at a greater rate, 
annually, than the CPI from 2005 through 2008, but appeared to level of in 2009, 
with tPA admission most closely following the CPI. Utilization of tPA increased in 
2005 from 1.84% to 5.47% in 2010. The number of admissions with MT increased 
from 0.87% to 8.09% over the same time period. Charges for AIS admissions have 
increased much more rapidly than the CPI observed from 2005 to 2010, with 
admissions receiving tPA having the greatest gain in charges. CONCLUSIONS: 
Cost of care for AIS patients who receive tPA follows the CPI trend, while costs 
for non-tPA patients increase at a greater rate. This disparity could indicate a 
widening gap between cost and reimbursement for non-tPA admissions, and/or a 
failure of many hospitals to accurately record the use of tPA for billing purposes.  
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REVIEW OF COST-UTILITY ANALYSES IN ASIA  
Thorat T, Lin PJ, Neumann PJ 
Tufts Medical Center, Boston, MA, USA  
OBJECTIVES: To review published cost-utility analyses (CUA) targeted towards 
Asian populations and to understand the cost-effectiveness of the interventions 
studied. METHODS: We used the Tufts Medical Center Cost-Effectiveness 
Analysis Registry (www.cearegisty.org) to identify English-language CUAs 
pertaining to Asian countries published from 2000-2011. We examined 
prevention stage, type of interventions, and disease areas associated with 
“favorable” ratios, which we defined ratios less than the median of all 
incremental cost-effectiveness ratios (ICERs, expressed as $US2011 per QALY) in 
Asian CUAs. RESULTS: Of 2,717 CUAs published during 2000-2011, 109 (4.0%) 
pertained to Asian countries: Japan (n=43), Taiwan (n=23), China (n=11), 
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Singapore (n=9), Hong Kong (n=6), Thailand (n=6), South Korea (n=6), India (n=5), 
Bangladesh (n=1), and Iran (n=1) (some studies pertain to more than one 
country). The CUAs contained 294 ICERs and 436 utility weights. The median 
ICER for all Asian CUAs was $11,000/QALY. The median ICER for tertiary 
prevention interventions ($9,800/QALY, n=157) was favorable, compared to the 
ICERs for primary and secondary prevention interventions ($22,000/QALY, n=69 
and $33,000/QALY, n=62); (p<0.005). The median ICER for immunizations was 
most favorable ($2,300/QALY, n=33), followed by surgical interventions, 
diagnostic interventions and pharmaceuticals and medical devices. In contrast, 
screening programs reported the least favorable ratios ($37,000/QALY, n=90). 
Studies examining infectious diseases had a lower median ICER ($8,500/QALY, 
n=43), compared to ICERs for interventions for cardiovascular diseases and 
cancer. CONCLUSIONS: Over 100 English-language CUAs targeted toward Asian 
countries have been published in English-language journals in recent years. 
Compared to interventions for primary and secondary prevention, interventions 
targeted towards treatments were relatively cost-effective. ICERs for screening 
programs have been relatively cost-ineffective.  
 
PRM34  
WHY ARE THE FINDINGS OF COST-EFFECTIVENESS ANALYSES OF BIOLOGIC 
TREATMENT FOR RHEUMATOID ARTHRITIS SO DIFFERENT?  
Druyts E1, Thorlund K2, Mills E3 
1University of Ottawa, Ottawa, ON, Canada, 2McMaster University, Hamilton, ON, Canada, 
3Stanford University, Palo Alto, CA, USA  
OBJECTIVES: To evaluate the quality of published cost-effectiveness analyses of 
biologic disease modifying antirheumatic drugs (bDMARDs) for rheumatoid 
arthritis (RA), and to identify methodological issues that can explain the 
discrepancies in the findings of these cost-effectiveness analyses. METHODS: We 
performed a systematic literature review to identify cost-effectiveness analyses 
of biologics indicated for RA. We compared the incremental the cost-
effectiveness ratios (ICERs), the net health benefits (NHB), the net monitory 
benefits (NMB), cost-effectiveness acceptability curves (CEACs), and cost-
effectiveness frontiers. RESULTS: We observed large discrepancies, which were 
predominantly due to the use of different information sources on the 
effectiveness of the considered biologics. First, substantial differences were 
observed in the ICER, NHB, NMB estimates. When considering the uncertainty 
associated with the NHB and NMB estimates, i.e. their 95% confidence intervals, 
differences were still apparent. CEACs and cost-effectiveness frontiers were only 
reported in a sub-set of the identified publications. Reading from the CEACs and 
cost-effective frontier graphs, fixed willingness to pay thresholds yielded 
different probabilities of the considered biologics being cost-effective. 
CONCLUSIONS: Cost-effectiveness analyses of biologics indicated for RA need to 
carefully consider the source of information used as model inputs. Future cost-
effectiveness analyses need to assess the large number of evidence synthesis 
studies conducted on the relative effectiveness of biologics when determining 
the appropriate model inputs.  
 
PRM35  
ECONOMICS OF COSTS IN ADDED YEARS OF LIFE: A REVIEW OF 
METHODOLOGIC PRACTICES AND CONSEQUENCES FOR COST-EFFECTIVENESS  
Olchanski N1, Zhong Y1, Saret CJ1, Cohen JT1, Bala M2, Neumann PJ1 
1Tufts Medical Center, Boston, MA, USA, 2Sanofi, Cambridge, MA, USA  
OBJECTIVES: There is some disagreement in the literature as to whether analysts 
should include all “future” costs or make distinctions between related and 
unrelated medical costs. Most guidelines lack definitive recommendations and 
urge analysts to use discretion or to employ sensitivity analysis to show how 
different approaches influence results. This study evaluated cost methods used 
in the published literature and evaluated the impact on cost-effectiveness of 
including different cost categories. METHODS: Systematic review included cost-
utility analyses from the Tufts CEA Registry published since 2000. We included 
cancer intervention studies where the intervention extended life expectancy. We 
identified specific types of costs included, and whether they varied by study 
characteristics such as cancer type, intervention type, country, perspective, 
conclusions. Further, we estimated alternative incremental cost-effectiveness 
ratios (ICERs) in which the ratio reflected different cost categories, including net 
costs due to study intervention, related medical costs of the treated condition, 
and unrelated medical costs. RESULTS: Of the 59 studies reviewed, none 
included medical costs unrelated to the treated condition, and 14 studies (24%) 
excluded direct medical costs related to the condition but not the evaluated 
intervention. Most studies assumed a health care payer perspective, included 
pharmaceutical interventions and reported ratios below $50,000/QALY. A greater 
proportion of government than industry studies included nonmedical costs. 
Recomputing ICERs by eliminating medical costs not affected by the evaluated 
intervention made 26 additional ratios (68%) cost-saving and 4 more ratios (11%) 
cost-effective. Recomputing ICERs by including unrelated medical costs made 6 
fewer ratios (10%) cost-saving and 4 fewer ratios (7%) cost-effective. 
CONCLUSIONS: Conventional CE methods may implicitly penalize therapies that 
add “expensive” life years for chronically ill patients. Presenting ICERs computed 
with and without disease-attributable costs can help better convey how much 
the treatment itself contributes to overall costs. Inclusion of unrelated medical 
costs affects ICERs less strongly.  
 
PRM37  
USING THE QUALITY OF HEALTH ECONOMIC STUDIES INSTRUMENT TO 
ASSESS PHARMACOECONOMIC STUDIES EVALUATING RECENT FOOD AND 
DRUG ADMINISTRATION DRUG APPROVALS  
Woersching AL, Borrego M, Raisch DW 
University of New Mexico College of Pharmacy, Albuquerque, NM, USA  
OBJECTIVES: To determine study quality, estimate quality scoring reliability, and 
assess theorized quality predictors of pharmacoeconomic publications 
evaluating recent new molecular entity and biologic license approvals (NMEs) by 
the Food and Drug Administration (FDA). METHODS: Original 
pharmacoeconomic studies (cost-effectiveness, cost-utility, cost-benefit or cost-
minimization) considering any of 50 NMEs approved in 2008-09 and published on 
or before December 31, 2011 were eligible. MEDLINE and the UK National Health 
Service Economic Evaluation Database were searched. Quality was scored with 
the Quality of Health Economic Studies (QHES) instrument for each publication 
by one primary and two secondary reviewers. Interrater reliability was assessed 
using Pearson correlations of QHES scores. Regression was performed of QHES 
score on study characteristics including number of authors, journal impact factor 
one-year pre-submission, journal type (disease-specific/general clinical/health 
economic), NME FDA review classifications (priority/standard and orphan/non), 
publication timing (pre-/post-NME approval), author(s) having academic 
affiliation (yes/no), advanced modeling PE techniques (yes/no), United States 
study (yes/no), data (primary/secondary), incorporation of quality-adjusted life 
years (yes/no), and conclusion (favorable/unfavorable for NME). RESULTS: The 
literature search yielded 203 search results with 37 publications meeting 
inclusion criteria, encompassing 38% of the 2008-09 NMEs. Averaging all 
reviewers, the QHES score range was 15-92, with a median 70, and mean 
68.4±18.4. The total QHES score was significantly correlated between reviewers 
(R= 0.677). A square transformation was applied to QHES score to correct for a 
negatively skewed distribution. Regression analyses were non-significant for all 
study characteristics, although use of advanced modeling PE techniques 
approached significance (p=0.083). CONCLUSIONS: QHES scores indicated that 
the quality of pharmacoeconomic literature for newly-approved NMEs varies, 
although the 51.3%, 19, highest scoring studies (including and above the median) 
were near or exceeded the 75 point threshold considered “good”. Interrater 
reliability for QHES assessment was fair. Sample size was insufficient to identify 
significant predictors among the variables analyzed.  
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A SYSTEMATIC REVIEW ON THE QUALITY OF PHARMACOECONOMICS STUDIES 
IN CHINA  
Jiang S1, Ma X2, Desai P3, Rascati KL1 
1The University of Texas at Austin, Austin, TX, USA, 2The University of Texas at Austin, Austin, 
TX, Austin, TX, USA, 3The University of Texas, Austin, TX, USA  
OBJECTIVES: To evaluate the extent and quality of published 
pharmacoeconomics studies based in China. METHODS: A systematic literature 
search was conducted using PubMed, Web of Science, and Google Scholar to 
identify pharmacoeconomics studies conducted in China. The keywords 
included different combinations of the following: health economics, 
pharmacoeconomics, cost-effectiveness, and China. The inclusion criteria for the 
studies were as follows: 1) original research articles; 2) written in English; 3) 
compared a pharmaceutical to another pharmaceutical, treatment modality, or 
no treatment; and 4) conducted in China. The articles were reviewed by two 
independent reviewers using the 100- point Quality of Health Economic Studies 
(QHES) scale for pharmacoeconomic studies and a subjective 10-point scale for 
cost studies. Disagreements were settled by a third researcher. General and 
economic analysis information of the articles was collected. RESULTS: A total of 
19 studies were included. The studies were published in 11 different journals 
between 2006 and 2012 with an average of five authors (SD=2.5). The mean QHES 
scores for the 17 pharmacoeconomic studies was 80.4 (SD=9.9) and the mean 
quality score for the two cost studies was 7.0 (SD=0.7). More than two-thirds of 
the authors resided in China (68.4%) and most of them had a medical 
background (89.5%). Most studies were published in journals based in foreign 
countries (not China) (89.5%) and used modeling as their study design (80.0%). 
Articles published in foreign journals had a higher quality score but the 
difference was not significant (80.5 ± 9.7 vs 69.0 ± 8.5). CONCLUSIONS: China-
based pharmacoeconomics studies written in English are limited, but on average, 
are of good quality. Economic evaluation of pharmaceuticals should be 
encouraged in China because appropriate allocation of health care resources is 
important in a country with large unmet medical needs.  
 
PRM39  
TRENDS IN COST EFFECTIVENESS OF HIGH BUDGET IMPACT PRODUCTS  
Aggarwal S, Messenger M 
Novel Health Strategies, Bethesda, MD, USA  
OBJECTIVES: The recently made coverage decisions by the UK's NICE, Scotland's 
SMC and the allocation of $1.1 billion for comparative effectiveness research by 
the U.S. are strong indicators of trends in pricing and reimbursement that are 
likely to be observed in the future. To gain an additional insight into these 
trends, we analyzed the cost effectiveness studies for the top twenty highest 
selling drugs (~$90-100B worldwide sales). METHODS: The Top 20 drugs were 
selected based on their worldwide sales. For this analysis, we segmented these 
drugs into categories such as primary care, specialty, small molecules, biologics, 
therapy areas, and availability of generic alternatives. We analyzed the cost 
effectiveness studies that were published in peer-reviewed journals. Searches 
were conducted using generic names of the drugs and the phrase “cost 
effectiveness” in an abstract of the published study. RESULTS: Between 2007-
2012, the number of published studies on “cost effectiveness” has increased by 
more than 32%. There is a large variability in CERs for same drugs for different 
indications, in some cases also varying by biomarkers. Primary care drugs had 
lower and less variable CERs than specialty drugs. Variations also exist in 
methodology used by different groups in modeling cost effectiveness, especially 
for time horizon and comparator. The majority of primary care drugs were 
